BRIEF-Lipocine Announces Completion Of Enrollment And Dosing In Phase 3 Trial Of LPCN 1154 In Postpartum Depression

Reuters
Jan 20
BRIEF-Lipocine Announces Completion Of Enrollment And Dosing In Phase 3 Trial Of LPCN 1154 In Postpartum Depression

Jan 20 (Reuters) - Lipocine Inc LPCN.O:

  • LIPOCINE ANNOUNCES COMPLETION OF ENROLLMENT AND DOSING IN PHASE 3 TRIAL OF LPCN 1154 IN POSTPARTUM DEPRESSION $(PPD)$

  • LIPOCINE INC - TOPLINE RESULTS EXPECTED EARLY Q2 2026

Source text: ID:nPn6zPhKTa

Further company coverage: LPCN.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10